Phase 1/2 Trial Results for Tinengotinib (TT-00420) in mCRPC

Tinengotinib (TT-00420), a multikinase inhibitor with a distinctive target profile, is showing early signals in metastatic castration‑resistant prostate cancer (mCRPC), a setting where options after modern androgen‑receptor pathway inhibitors and taxanes remain limited. Results from a US‑based, multicenter phase 1/2 trial, published in Clinical Cancer Research, reported an objective response rate of 33.3% in a small, heavily pretreated prostate cancer cohort (15 patients), alongside a manageable safety profile dominated by hypertension and relatively infrequent hyperphosphatemia or ocular toxicity compared with some FGFR‑selective agents. While the numbers are small and exploratory, they are large enough to justify closer attention to how a drug that simultaneously hits Aurora kinases A/B, FGFR1–3, VEGFR2, and JAK1/2 might fit into the evolving biology of treatment‑resistant prostate cancer.

The rationale for testing tinengotinib in prostate cancer rests on converging lines of preclinical and clinical evidence that go beyond a single “driver” mutation. Aurora kinases regulate mitosis and are frequently overexpressed in aggressive prostate cancers; their inhibition can induce mitotic catastrophe and sensitize tumors to other therapies. FGFR signaling, while less classically “prostate” than in cholangiocarcinoma or urothelial cancer, is activated in subsets of mCRPC through amplifications, mutations, or pathway crosstalk, and has been implicated in resistance to androgen‑deprivation and AR‑targeted agents. VEGFR2 inhibition adds an anti‑angiogenic component that may be particularly relevant in bone‑predominant disease, while JAK1/2 blockade modulates inflammatory and immune pathways that intersect with AR signaling, neuroendocrine differentiation, and treatment‑emergent small‑cell phenotypes. By hitting these nodes at once, tinengotinib is designed to attack proliferation, angiogenesis, and immune‑oncologic escape in parallel, rather than betting on a single alteration.

In the phase 1/2 study, tinengotinib was given orally, with key arms evaluating 12 mg once daily and other dose levels/schedules; pharmacokinetic and efficacy data ultimately supported a 10 mg once‑daily regimen for further development. Among 197 patients with diverse solid tumors, 15 had prostate cancer; in this subgroup, one‑third achieved an objective radiographic response, a signal that stands out against the backdrop of a disease where most single‑agent targeted therapies yield modest response rates outside of DNA‑repair–deficient subsets. Clinical benefit, defined as complete or partial response or stable disease lasting at least six months, was observed in a meaningful fraction of evaluable patients overall, and the prostate cancer cohort contributed to the impression that antitumor activity was most pronounced at the 10‑mg and 12‑mg dose levels. Safety was consistent with the drug’s mechanism: hypertension was the most common treatment‑related adverse event, while hyperphosphatemia and ocular toxicities, often dose‑limiting with selective FGFR inhibitors, were uncommon, an attribute that could be advantageous for long‑term use in a chronic disease like mCRPC.

NOTE: tinengotinib is currently being studied in another phase 1/2 trial, focused on prostate cancer only, in combination with abiraterone acetate and prednisone or enzalutamide in mCRPC (link at the bottom of the page).

Perhaps the most provocative aspect of the report for prostate cancer is not the headline response rate but the exploratory genomic correlates that point toward a biology‑driven selection strategy. The authors observed that alterations in MYC were associated with shorter progression‑free survival in prostate cancer patients treated with tinengotinib, a finding that dovetails with emerging work linking MYC‑driven lineage plasticity to androgen‑receptor–independent disease, neuroendocrine features, and aggressive, treatment‑resistant phenotypes. This does not mean that MYC‑altered tumors cannot respond; rather, it suggests that MYC activation may mark a state where single‑agent multikinase inhibition is insufficient, and where rational combinations might be required to overcome plasticity and sustain benefit. At the same time, reductions in circulating tumor DNA variant allele frequency during treatment provided pharmacodynamic evidence of target engagement, reinforcing the idea that tinengotinib is hitting its intended pathways in vivo and that ctDNA could be used to monitor response and resistance in future prostate‑specific studies.

Source.

Clinical trial